Immuneering’s CEO walks us through the company’s MEK data in pancreatic cancer, and explains the science behind ‘deep cyclic inhibition’
Immuneering’s CEO walks us through the company’s MEK data in pancreatic cancer, and explains the science behind ‘deep cyclic inhibition’